Company TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
0.82 ^USD	+15.98%		+49.12%	-87.56%

04-22	Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI
04-22	Certain Stock Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 22-APR-2024.	CI

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Companyâs lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Companyâs pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.

Number of employees: 10

Managers	Title	Age	Since
Thomas Fitzgerald CEO	Chief Executive Officer	73	18-06-30
Zdravka Medarova FOU	Founder	50	15-12-31
Susan Duggan COO	Chief Operating Officer	-	-
Alan Freidman IRC	Investor Relations Contact	-	-
Seth Gregg PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Magda Marquet BRD	Director/Board Member	65	20-12-31
Philippe Calais CHM	Chairman	65	18-09-30
Erik Manting BRD	Director/Board Member	53	20-12-19
Thomas Fitzgerald CEO	Chief Executive Officer	73	18-06-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,108,053	5,799,563 ( 94.95 %)	0	94.95 %

Name	Equities	%	Valuation
The Lind Partners LLC 0.4000 %	26,279	0.4000 %	17 949 $
Citadel Securities GP LLC 0.1073 %	7,048	0.1073 %	4 814 $
Renaissance Technologies LLC 0.0713 %	4,685	0.0713 %	3 200 $
Robert Dudley 0.0686 %	4,507	0.0686 %	3 078 $
Zdravka Medarova 0.0368 %	2,416	0.0368 %	1 650 $
Thomas Fitzgerald 0.0214 %	1,408	0.0214 %	962 $
Geode Capital Management LLC 0.0199 %	1,306	0.0199 %	892 $
CapFinancial Partners LLC 0.0190 %	1,250	0.0190 %	854 $
HRT Financial LLC 0.0133 %	874	0.0133 %	597 $
G1 Execution Services LLC 0.004186 %	275	0.004186 %	188 $

TransCode Therapeutics, Inc.

6 Liberty Square Suite 2382

02109, Boston

http://www.transcodetherapeutics.com

address TransCode Therapeutics, Inc.(RNAZ)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.707 USD

Average target price

3 USD

Spread / Average Target

+324.33%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
TRANSCODE THERAPEUTICS, INC.	-87.56%	4.32M
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	103B
REGENERON PHARMACEUTICALS, INC.	+8.96%	101B
ARGENX SE	+4.40%	23.07B
BIONTECH SE	-12.15%	22.23B
GENMAB A/S	-4.36%	18.05B
WUXI APPTEC CO., LTD.	-39.98%	17.18B
BEIGENE, LTD.	-10.04%	16.94B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.07B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.35B

Bio Therapeutic Drugs